Specific examples include the use of EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with an EGFR mutation [8], BRAF inhibitors in melanoma harboring BRAF mutations [9,10], or imatinib for chronic myelogenous leukemia [11,12]. Here, BRAF is linked to non-small cell lung carcinoma.